Neogen Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY27 revenue reached $222.8 million, with 8.1% core growth and adjusted EBITDA margin expansion of 170 bps. FY27 revenue and adjusted EBITDA guidance were raised, while Petrifilm transfer and debt reduction remain key priorities.
Fiscal Year 2026
-
The plan moves from FY26 stabilization to FY27 acceleration and FY28 expansion, targeting high-single-digit to low-double-digit growth, high-50% gross margin, ~30% adjusted EBITDA margin and 80% FCF conversion by FY31. Growth relies on solutions selling, innovation and operating leverage.
-
The meeting confirmed a quorum and addressed five proposals, all of which passed with strong shareholder support. Directors were elected, executive compensation was approved, auditors were ratified, and incentive and stock purchase plans were amended. No questions were raised during the Q&A.
-
Q4 saw strong core growth in both food and animal safety, with food safety up 5.8% and gross margin improving 330 bps year-over-year. FY27 guidance targets $880–$885M revenue and 20.5% EBITDA margin, with major investments in R&D and operational efficiency planned.
-
Core food safety growth remained strong, with adjusted EBITDA margin at 22.8% and revenue guidance raised to $857–$860 million. Animal safety faced supply chain headwinds, but operational and innovation initiatives are underway to drive future margin and cash flow improvements.
-
A new leadership team is driving a turnaround with a three-stage strategy focused on stabilization, growth, and innovation. The company is refocusing its portfolio, investing in R&D, and expects to divest its genomics division by year-end. Q2 results exceeded expectations, supporting cautious optimism for sustained recovery.
-
Q2 saw a return to positive core growth and significant margin improvement, with revenues up 2.9% year-over-year and adjusted EBITDA margin rising nearly 500 basis points sequentially. Full-year guidance was raised, reflecting strong execution, cost savings, and ongoing transformation initiatives.
-
Q1 revenue was $209M, up 0.3% year-over-year, with adjusted EBITDA margin at 17%. Cost reductions and operational improvements are underway, with full-year guidance reaffirmed and sequential margin improvement expected as process enhancements take effect.
Fiscal Year 2025
-
Q4 revenue declined year-over-year amid soft end markets, inventory and production challenges, and tariff headwinds. Guidance for fiscal 2026 anticipates modest revenue growth, improved margins in the second half, and positive free cash flow, with continued focus on operational improvements and divestitures.
-
Food safety testing now dominates the portfolio following a major acquisition, with two divestitures in progress to streamline operations and reduce debt. Market growth has slowed due to inflation and trade uncertainty, but operational improvements and integration milestones are expected to drive recovery and margin normalization over the next year.
-
Third quarter results missed expectations due to macro uncertainty, softening end markets, and tariff impacts. Food safety core revenue grew 7% excluding sample collection, while animal safety and genomics faced headwinds. Full-year guidance was lowered, with cost actions and portfolio focus underway.
-
The presentation highlighted strong secular tailwinds in food safety, ongoing regulatory changes, and a broadening product portfolio following the 3M integration. Despite recent market headwinds and a reduction in revenue guidance, operational improvements and portfolio optimization are positioning the business for renewed growth and margin expansion.
-
Q2 saw sequential improvements in revenue, margin, and cash flow, with core revenue up 3.5% year-over-year despite FX headwinds. Guidance was reduced due to FX, genomics restructuring, and sample collection delays, but margin improvement is expected in the second half.
-
Q1 revenue declined slightly year-over-year, with Food Safety showing core growth but Animal Safety and Genomics segments facing headwinds. Guidance for fiscal 2025 is maintained, with expectations for stronger performance in the second half and ongoing focus on integration, efficiency, and international expansion.
Fiscal Year 2024
-
Q2 revenue reached $230 million with sequential core growth improvement and positive animal safety trends. Integration of the 3M food safety business is nearly complete, and international expansion is driving growth. Margin initiatives and a shift toward larger acquisitions are expected to support future performance.
-
First quarter results met expectations, with operational challenges from the 3M integration largely resolved and only Petrifilm manufacturing integration remaining. Growth is expected to be driven by international expansion, innovation, and operational leverage, while free cash flow turns positive as integration spending declines.
-
Q4 saw modest core revenue growth and strong innovation, despite headwinds from distribution inefficiencies and soft end markets. Integration milestones were achieved, and FY25 guidance anticipates margin expansion, lower CapEx, and positive free cash flow.
-
The company is advancing food safety and animal health globally, leveraging innovation in diagnostics, data analytics, and genomics. Integration of recent acquisitions is nearly complete, with new manufacturing capacity and strong financial outlook supporting growth in under-penetrated markets.